sponsored
PatientsVille.com Logo

PatientsVille

Avon Medical Research Studies

Up-to-date List of Avon Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Avon Medical Research Studies

Rank Status Study
1 Recruiting Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness
Condition: Prostate Cancer
Interventions: Drug: Purified Isoflavones;   Drug: Methyl cellulose blend
Outcome Measures: Incidence of Change in Percent Ki-67;   Incidence of Adverse Events (AEs);   Biomarkers of Disease Progression.;   Expression Levels of Isoflavone Participants
2 Recruiting Isoflavones and Magnolia Extract in the Quality of Life in Menopausal Women
Condition: Menopause
Intervention: Dietary Supplement: Isoflavones combined with magnolia
Outcome Measures: the quality of life measured by the scale of Cervantes;   Clinical changes in vasomotor symptomatology
3 Unknown  The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women
Condition: Postmenopausal Symptoms
Interventions: Drug: estradiol;   Drug: isoflavone;   Drug: Placebo
Outcome Measures: McCoy's sexual questionnaire;   Kupperman's index
4 Not yet recruiting Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Dietary Supplement: soy Isoflavones;   Drug: cisplatin;   Drug: etoposide;   Drug: pemetrexed disodium;   Radiation: radiation therapy
Outcome Measures: Safety, in terms of dose-limiting toxicity of adding oral soy isoflavone supplementation to concurrent chemotherapy and radiotherapy, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4;   Survival proportion;   Grade 3-4 toxicity rate graded according to NCI CTCAE version 4.0;   Response (complete response [CR] and partial response [PR]) rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;   Time to tumor progression (TTP);   Overall survival (OS);   Response duration
5 Recruiting Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Squamous Cell Carcinoma of the Hypopharynx;   Stage I Squamous Cell Carcinoma of the Larynx;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Larynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Squamous Cell Carcinoma of the Hypopharynx;   Stage II Squamous Cell Carcinoma of the Larynx;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Larynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: soy Isoflavones;   Other: laboratory biomarker analysis;   Other: survey administration
Outcome Measures: Change in p16 methylation (% CpG sites methylated) and expression of p16, COX-2, VEGF, EGFR, IL6, p53 and BclxL in tumor and non-tumor adjacent mucosa;   Correlations of tumor p16 methylation status with serum/saliva markers of p16, IL6, and VEGF;   Overall survival;   Relapse-free survival;   Incidence of observed toxicities
6 Recruiting Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
Condition: Cancer of Head and Neck
Intervention: Drug: soy isoflavone
Outcome Measures: Percentage of patients with grade 2 or higher xerostomia at 1 year post-treatment.;   Exploratory biomarker studies
7 Not yet recruiting Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome
Condition: Irritable Bowel Disease
Interventions: Dietary Supplement: Soy Isoflavones;   Dietary Supplement: cholecalciferol;   Dietary Supplement: Placebo of soy Isoflavones;   Dietary Supplement: placebo of cholecalciferol
Outcome Measures: Change from baseline in Clinical Outcomes (pain, flatulence, diarrhea, constipation ) at 6 weeks;   Change of baseline in gut permeability as efficacy at 6 weeks;   Change of baseline in antioxidant status as efficacy at 6 weeks;   Change of baseline in inflammation status as efficacy at 6 weeks
8 Unknown  A Taiwan Isoflavone Multicenter Study (TIMS)
Conditions: Low Bone Density;   Osteopenia
Intervention: Drug: Soy Isoflavone
Outcome Measures: BMD change;   Lipid profile
9 Not yet recruiting Estromineral Serena Plus and Symptomatic Menopause
Condition: Menopause
Interventions: Dietary Supplement: Estromineral Serena Plus;   Dietary Supplement: Estromineral
Outcome Measures: Kupperman index;   Adverse events
10 Unknown  Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause
Condition: Postmenopausal Women With Moderate Vasomotor Symptoms
Interventions: Drug: Soy Isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);   Drug: Placebo
Outcome Measures: Mean Change in the number of symptoms of hot flashes (including night sweats) at the end of the study (week 22) with respect to baseline (week 6).;   Intensity of Hot Flashes;   Impact of the treatment with FITOGYN on the overall symptoms of menopause: fatigue, joint pain, vaginal dryness and sleep disturbances among others.;   Effect of the treatment with FITOGYN in the level of anxiety of postmenopausal women.;   Effect of the treatment with FITOGYN in the quality of life of postmenopausal women.;   Evaluate the change in the subject's lipidic profile.;   Evaluation of the safety and tolerability.
11 Unknown  Soy Food Intervention Trial
Condition: Familial Hypercholesterolemia
Interventions: Dietary Supplement: soy protein diet;   Dietary Supplement: rapeseed oil
Outcome Measures: Blood analysis include: TC, LDLc, HDLc, TG, Lp(a), ApoA1, Apo B, Electrolytes, Albumin, Creatinin and CRP;   uric acid and the Isoflavones: daidzein, glycetein, genistein and equol
12 Unknown  Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause
Condition: Menopause
Interventions: Drug: Isoflavone;   Drug: Placebo
Outcome Measure: Concentration of serum DDimer
13 Not yet recruiting Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants
Conditions: Cardiovascular Disease;   Subclinical Hypothyroid
Interventions: Dietary Supplement: soy protein isolate (SPI);   Dietary Supplement: milk protein isolate (MPI)
Outcome Measures: Changes in the cardiometabolic profile;   Change in thyroid function
14 Recruiting Alternative Treatments for Menopausal Women
Conditions: Menopause;   Hot Flushes;   Osteoporosis;   Dyslipidemia
Interventions: Dietary Supplement: Placebo;   Dietary Supplement: Red Clover extract
Outcome Measure: Primary Menopause-related symptoms
15 Recruiting Kudzu Treatment for Alcohol Abuse
Condition: Alcohol Consumption
Interventions: Dietary Supplement: Kudzu;   Dietary Supplement: Placebo
Outcome Measure: Drinking behaviors
16 Unknown  Soy Nut Study on Markers of Health
Condition: Metabolic Syndrome X
Interventions: Other: Soy nuts;   Other: Matched food
Outcome Measures: Improve lipid profile;   Increase endothelial function;   Attenuate glycemic responses;   Decrease inflammatory markers;   Follow anthropometrics for stable weight
17 Not yet recruiting Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms
Condition: Climacteric Syndrome
Interventions: Drug: Placebo;   Drug: Active drug
Outcome Measures: Menopause Rating Scale - MRS;   Kuppperman-Blatt index;   MRS scale;   MENQOL
18 Recruiting Genistein as a Possible Treatment for Alzheimer's Disease.
Condition: Alzheimer's Disease
Interventions: Dietary Supplement: Genistein;   Other: Placebo
Outcome Measures: Amyloid beta concentration in cerebrospinal fluid (CSF). The primary study endpoint is the change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.;   MMSE. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.;   Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.;   Memory alteration test (M@t). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.;   Neuropsychiatric Inventory (NPI). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.;   Barthel index. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.;   P-TAU concentration in CSF. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.
19 Recruiting MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Drug: decitabine in combination with genistein
Outcome Measures: Maximum Tolerated Dose (MTD);   To determine the drug plasma concentrations of decitabine and genistein.;   Preliminary clinical efficacy assessment
20 Unknown  Influence of Nebivolol on Postmenopausal Women
Conditions: Hot Flashes;   Heart Rate;   Blood Pressure;   Endostatin;   Sexual Function
Intervention:
Outcome Measures: Number of hot flashes/palpitations;   Hemodynamic changes;   Sexual function;   Endostatin;   Quality of life

These studies may lead to new treatments and are adding insight into Avon etiology and treatment.

A major focus of Avon research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Avon